A longitudinal study on [alpha]-synuclein in blood plasma as a biomarker for Parkinson's disease

There have been no longitudinal studies on α-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total α-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-d...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2013-08, Vol.3, p.2540
Main Authors: Foulds, Penelope G, Diggle, Peter, Mitchell, J Douglas, Parker, Angela, Hasegawa, Masato, Masuda-suzukake, Masami, Mann, David M A, Allsop, David
Format: Article
Language:English
Subjects:
Longitudinal studies
Movement disorders
Neurodegenerative diseases
Parkinson's disease
Plasma
Synuclein
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There have been no longitudinal studies on α-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total α-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total α-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p = 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated α-synuclein, but not of total α-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p = 0.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total α-synuclein could act as a surrogate marker for the progression of PD.
ISSN:2045-2322
DOI:10.1038/srep02540